

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 2602-1-001
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/936198
INTERNATIONAL APPLICATION NO. PCT/GB00/00845	INTERNATIONAL FILING DATE 8 MARCH 2000	PRIORITY DATE CLAIMED 9 MARCH 1999	
TITLE OF INVENTION DIAGNOSTIC TEST			
APPLICANT(S) FOR DO/EO/US Alastair Campbell Agnew GLEN; and Donald John MCDONALD			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input checked="" type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). EXECUTED 10. <input checked="" type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 			
Items 11 to 20 below concern document(s) or information included:			
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input type="checkbox"/> Other items or information: 			
Copy of International Preliminary Examination Report; Copy of International Search Report; Copy of Written Opinion; Four (4) Sheets of Drawings attached to Published Application			

U.S. APPLICATION NO. (if known) 09/936198		INTERNATIONAL APPLICATION NO. PCT/GB00/00845		ATTORNEY'S DOCKET NUMBER 2602-1-001	
--	--	---	--	---	--

<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p> <p style="text-align: center;">ENTER APPROPRIATE BASIC FEE AMOUNT =</p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:20%;">\$</th> </tr> <tr> <td>Total claims</td> <td>35 - 20 =</td> <td>15</td> <td>x \$18.00</td> <td>\$ 270.00</td> </tr> <tr> <td>Independent claims</td> <td>6 - 3 =</td> <td>3</td> <td>x \$80.00</td> <td>\$ 240.00</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$270.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 1,640.00</td> </tr> </table> <p><input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. \$ 820.00</p> <p style="text-align: right;">SUBTOTAL =</p> <p>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p> <p style="text-align: right;">TOTAL NATIONAL FEE =</p> <p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</p> <p style="text-align: right;">TOTAL FEES ENCLOSED =</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:60%;"></td> <td style="width:20%;">Amount to be refunded:</td> <td style="width:20%;">\$</td> </tr> <tr> <td></td> <td>charged:</td> <td>\$</td> </tr> </table>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	35 - 20 =	15	x \$18.00	\$ 270.00	Independent claims	6 - 3 =	3	x \$80.00	\$ 240.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$270.00	TOTAL OF ABOVE CALCULATIONS =				\$ 1,640.00		Amount to be refunded:	\$		charged:	\$	CALCULATIONS PTO USE ONLY	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																																
Total claims	35 - 20 =	15	x \$18.00	\$ 270.00																																
Independent claims	6 - 3 =	3	x \$80.00	\$ 240.00																																
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$270.00																																
TOTAL OF ABOVE CALCULATIONS =				\$ 1,640.00																																
	Amount to be refunded:	\$																																		
	charged:	\$																																		

a. ☒ A check in the amount of \$ 860.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.


c. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 11-1153. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

DAVID A. JACKSON
KLAUBER & JACKSON
411 Hackensack Avenue, 4th Floor
Hackensack, New Jersey 07601
(201) 487-5800


 SIGNATURE
 DAVID A. JACKSON
 NAME
 26,742
 REGISTRATION NUMBER

PATENT
2602-1-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Alastair Campbell Agnew GLEN; Donald John MCDONALD
APPLICATION NO. : PCT/GB00/00845
FILED : March 8, 2000
FOR : DIAGNOSTIC TEST

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
BOX PCT
WASHINGTON, D.C. 20231

Sir:

Prior to calculating the fees pursuant to the entry into the National Phase of the above-identified Application, please amend the Claims as follows:

IN THE CLAIMS:

Please enter and consider Claims 1-33 appended hereto in place of the claims submitted and attached to the original International Application as filed under the Patent Cooperation Treaty.

1. An assay for detecting type IV cytosolic phospholipase A₂ (cPLA₂) or a protein immunologically homologous to type IV cPLA₂, the assay comprising obtaining a sample of red blood cells, and examining said red blood cells for the presence of said type IV cytosolic phospholipase A₂ (cPLA₂) or said protein immunologically homologous thereto.
2. An assay according to claim 1 for use in the diagnosis of a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated.

3. An assay according to claim 1 for use in monitoring the effectiveness of medication administered to a patient suffering from a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated
4. An assay according to claim 1 for use in drug development for a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated.
5. A method of diagnosis of a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cytosolic phospholipase A₂ (cPLA₂) protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells.
6. A method of monitoring the effectiveness of medication administered to a patient suffering from a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cytosolic phospholipase A₂ (cPLA₂) protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells.
7. A method of drug development for a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cytosolic phospholipase A₂ (cPLA₂) protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells.

8. An assay according to claim 1 wherein the red blood cells are isolated from the human body.
9. An assay according to claim 7 wherein said assay or method comprises use of a whole blood sample without prior isolation of said red blood cells.
10. An assay according to claim 2 wherein said disease is a disease or disease process in which type IV cPLA₂ activity or concentration is altered from normal levels.
11. An assay according to claim 2 wherein said disease is a disease or disease process in which type IV cPLA₂ activity or concentration is increased.
12. An assay according to claim 2 wherein the disease is schizophrenia, dyslexia, bipolar or manic depressive illness, cachexia or brain injury.
13. An assay according to claim 12 wherein the brain injury is stroke or mechanical brain injury.
14. An assay according to claim 1 wherein the type IV cPLA₂ protein or the protein immunologically homologous to type IV cPLA₂ has a molecular weight in the range 80 to 110 kDa or in the range 70 to 80 kDa or in the range 50 to 60 kDa.

15. An assay according to claim 1 wherein the type IV cPLA₂ protein or the protein immunologically homologous to type IV cPLA₂ has a molecular weight in the range 90 to 105 kDa or in the range 70 to 80 kDa or in the range 50 to 60 kDa.
16. An assay according to claim 1 comprising the steps of collecting a sample of blood from a subject and detecting the proteins *ex vivo*.
17. An assay according to claim 16 further comprising one or more of the steps of separating the red cells from the other blood components, disrupting the red cells, detecting the proteins either directly or following a protein separation technique.
18. An assay according to claim 17 wherein the red cells are disrupted by sonication, freezing, nitrogen cavitation or lysis.
19. An assay according to claim 1 wherein said proteins are detected by immunoassay.
20. An assay according to claim 1 wherein said proteins are detected using an antibody or antibodies that recognise an epitope or epitopes from amino acids 82 to 749 of type IV cPLA₂ protein from human monocyte (U937) cells.
21. An assay according to claim 1 wherein said proteins are detected using an antibody or antibodies raised against an epitope or epitopes from amino acids 82 to 749 of type IV cPLA₂

protein from human monocyte (U937 cells) or raised against an epitope or epitopes of a synthetic peptide matching amino acids 82 to 749 of type IV cPLA₂ protein from human monocyte (U937) cells.

22. An assay according to claim 20 or 21 wherein said epitope or epitopes are from a peptide sequence or sequences which comprise the catalytic centre of type IV cPLA₂ protein from human monocyte (U937) cells.

23. An assay according to claim 20 or 21 wherein said epitope or epitopes are from the peptide sequence of amino acids 241 to 260 of type IV cPLA₂ protein from human monocyte (U937) cells.

24. An assay according to claim 19 wherein said proteins are detected using an antibody or antibodies raised against an epitope or epitopes from amino acids 1 to 216 of type IV cPLA₂ protein from human monocyte (U937) cells.

25. An assay according to claim 20, wherein two or more of the antibodies are used in combination or in sequence to detect the said proteins with the required specificity.

26. An assay according to claim 1 for detecting type IV cPLA₂ wherein said proteins are detected by substrate assay.

27. A protein other than type IV cPLA₂ obtainable by isolation from red blood cells, said protein being immunologically homologous to type IV cPLA₂ and having a molecular weight in the range 80 to 110 kDa or a molecular weight in the range 70 to 80 kDa or a molecular weight in the range 50 to 60 kDa.

28. A protein according to claim 27, said protein being immunologically homologous to type IV cPLA₂ and having a molecular weight in the range 90 to 105 kDa or a molecular weight in the range 70 to 80 kDa or a molecular weight in the range 50 to 60 kDa.

29. A diagnostic kit comprising means for disrupting red blood cells and further comprising an antibody or antibodies to a protein obtainable by isolation from red blood cells, said protein being type IV cPLA₂ protein or a protein immunologically homologous to type IV cPLA₂.

30. A diagnostic kit according to claim 28 wherein said antibody or antibodies is/are raised against an epitope or epitopes from amino acids 82 to 749 of type IV cPLA₂ protein from human monocyte (U937) cells.

31. A diagnostic kit according to claim 28 wherein said antibody or antibodies is/are raised against an epitope or epitopes from a peptide sequence or sequences which comprise the catalytic active centre of type IV cPLA₂ protein from human monocyte (U937) cells.

32. A diagnostic kit according to claim 28, wherein said means for disrupting red blood cells is a means for lysing red blood cells.

33. A diagnostic kit according to claim 28, which is suitable for near-patient testing.

REMARKS


Attached Claims 1-33 are submitted herewith in place of the claims that were included with the original International Application as filed, and represent revisions to such claims so as to place them in greater conformity with U.S. practice and claim format. The substance of the attached claims is commensurate in scope with that of the Application as filed, and merely seeks to better conform with the requirements for claims that are imposed under the U.S. Patent Laws.

Specifically, the above amendment is primarily taken from the claims that were originally submitted with the Patent Cooperation Treaty Application on filing, and makes certain amendments thereto, so that the resulting claims should be considered in place of those claims that were amended during the examination phase of the pendency of the International Application.

In all of the respects, the Application as filed is believed to be in proper form, and prompt and favorable processing before the U.S. Patent and Trademark Office is accordingly courteously solicited.

Entry of the foregoing amendments and early and favorable processing in the National Phase before the United States Patent and Trademark Office is courteously solicited.

Respectfully submitted,



DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800

DIAGNOSTIC TEST

The present invention is concerned with identification of proteins of the cytosolic phospholipase A₂ enzyme and the applications thereof, particularly in diagnosis, treatment
5 monitoring and drug development.

Phospholipase A₂ (PLA₂) enzymes are generally characterised by their capacity to catalyse the hydrolysis of the Sn2 acyl-ester bond of glycerophosphate to release free fatty acid (Mayer R.J. and Marshall L., *FASEB J*, 7, 339-348; Dennis E.A., Ed., Phospholipase
10 A₂ Methods in Enzymology, 1991, 197, 359-433). The scientific literature recognises different types of PLA₂ enzyme (Dennis E.A., *Trends Biochem. Sci.*, 22, 1-2). Types I, II and III are referred to as secretory phospholipase A₂ (sPLA₂) enzymes. Secretory phospholipase A₂ enzymes have a molecular weight of approximately 14 kDa, are found extracellularly and have been recognised in plasma.

15 The type IV PLA₂ enzyme is referred to as cytosolic phospholipase A₂ (cPLA₂). It features a calcium binding domain, termed the C2 domain, and its phospholipase activity is highly selective for highly-unsaturated fatty acids, particularly arachidonic acid, present in the Sn2 acyl-ester glycerophosphate bond. Its ability to release arachidonic acid from cell
20 membrane phospholipids sets it in a key position for the regulation of the supply of arachidonate and subsequent action in cell messenger processes.

A further type of PLA₂ enzyme is the type VI enzyme which is also a cytosolic PLA₂ enzyme, but which does not possess the high selectivity for arachidonic acid in the
25 Sn2 position of glycerophosphate for phospholipid acyl ester hydrolysis (Tang J. *et al.*, *J Biol. Chem.*, 272, 1997, 8567-8575). It is termed iPLA₂ in recognition that it is independent of calcium level for its catalytic activity.

The type IV arachidonate-selective cPLA₂ enzyme has been identified in a number
30 of tissues including human monocytes (Clark J.D. *et al.*, *Cell*, 65, 1991, 1043-1051; Kramer R.M. *et al.*, *J. Biol. Chem.*, 266, 1991, 5268-5272) and human platelets (Takayama K. *et al.*, *FEBS*, 282, 1991, 326-330).

The amino acid sequence of type IV cPLA₂ has been determined for the enzyme purified from human monocyte (U937) cells (Clark J.D. *et al.*, *Cell*, 65, 1991, 1043-1051). Type IV cPLA₂ found in U937 cells has an amino acid sequence which is 749 amino acids long. This sequence shows a region of homology with a limited number of other proteins including protein kinase C (PKC), GTPase activating protein (GAP), phospholipase C and synaptic vesicle protein p65. The points of homology occur towards the N-terminal end of the protein in the so-called calcium-binding portion which is at or around amino acids 36 to 81 of the sequence (counting from the NH₂ terminal end) (Nalefski *et al.*, *J. Biol. Chem.*, 269, 18239-18249). There are no known areas of sequence homology between other mammalian proteins and type IV cPLA₂ amino acids 82 to 749, apart from a sequence from amino acids 129 to 135 shared with pulmonary surfactant protein C (Clark *et al.*, *J. Lipid Mediators Cell Signalling*, 12, 83-117) and two recently reported cytosolic phospholipase A₂ enzymes designated cPLA₂β and cPLA₂γ (R.T. Pickard *et al.*, *J. Biol. Chem.*, 1999, 274, 8823-8831). These are proteins different from the cPLA₂ enzyme isolated from human U937 monocytes (which now may be designated as cPLA₂α). The cPLA₂α, β and γ sequence homology is limited to five amino acids found in cPLA₂α at position serine 228 to tryptophan 232.

The catalytic active centre of type IV cPLA₂ has been reported as being located in a peptide sequence comprising amino acid 228 (Clark J.D. *et al.*, *J. Lipid Mediators Cell Signalling*, 12, 83-117) and has recently been described as being dependent for its function on the proximity of two amino acids brought together in the folded tertiary structure of the molecule, serine 228 and aspartate 549 (Dessen A. *et al.*, *Cell*, 1999, 97, 349-360).

Previous observations of PLA₂ enzymes in the circulation have been directed at measurements in serum or plasma by substrate assay methods and have not characterised the type of the enzyme involved (Thuren T. *et al.*, *Clin.Chem.*, 31, 1985, 714-717; Gattaz W.F. *et al.*, *Biol. Psychiatry*, 22, 1987, 421-426; Gattaz W.F. *et al.*, *Biol. Psychiatry*, 28, 1990, 495-501). Serum and plasma PLA₂ enzymes show increased activity relative to normal control subjects in the human disease schizophrenia, although again the PLA₂ type of the enzyme responsible has not been characterised. To date, there has been no identification of cytosolic phospholipase A₂ type IV protein either in or attached to red cells either physiologically or in pathology.

It has now been found that type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂ can be detected in or on circulating red blood cells. The detection and assay of these cPLA₂ proteins has application in the diagnosis of disease, in the monitoring of the patient response to treatment and in the development of drugs which influence the activity or concentration of cPLA₂. Recognition that these cPLA₂ proteins may be detected in or on red blood cells provides a simple and convenient method of assaying for the cPLA₂ level.

According to a first aspect of the present invention, there is provided an assay for detecting type IV cPLA₂ or a protein immunologically homologous to type IV cPLA₂, the assay comprising use of red blood cells. In a second aspect of the invention, there is provided an assay for quantifying the level of type IV cPLA₂ or a protein immunologically homologous to type IV cPLA₂ in a sample of red blood cells. The assay may be performed on a sample of whole blood or on a sample of red blood cells after separation thereof from whole blood.

As used herein, the term "a protein immunologically homologous to type IV cPLA₂" means a protein that binds specifically to an antibody or antibodies that recognise an epitope or epitopes from any part of type IV cPLA₂ protein from human monocyte (U937) cells, and preferably an epitope or epitopes from amino acids 82 to 749 of type IV cPLA₂ protein from human monocyte (U937) cells. In a preferred embodiment of the invention, the term "a protein immunologically homologous to type IV cPLA₂" means a protein that binds specifically to an antibody or antibodies that recognise an epitope or epitopes from a peptide sequence or sequences which comprise the catalytic active centre of type IV cPLA₂ protein from human monocyte (U937) cells. In a further preferred embodiment, the term "a protein immunologically homologous to type IV cPLA₂" means a protein that binds specifically to an antibody or antibodies that recognise an epitope or epitopes from the peptide sequence of amino acids 241 to 260 of type IV cPLA₂ protein from human monocyte (U937) cells.

In an alternative embodiment, the term "a protein immunologically homologous to type IV cPLA₂" means a protein that binds specifically to an antibody or antibodies raised against an epitope or epitopes from any part of type IV cPLA₂ protein from human

monocyte (U937) cells or a synthetic peptide matching the sequence of type IV cPLA₂ protein from human monocyte (U937) cells. In a preferred alternative embodiment, the term "a protein immunologically homologous to type IV cPLA₂" means a protein that binds specifically to an antibody or antibodies raised against an epitope or epitopes from amino acids 82 to 749, and preferably an epitope or epitopes from a peptide sequence or sequences which comprises the catalytic active centre, of type IV cPLA₂ protein from human monocyte (U937) cells or a synthetic peptide matching the sequence of amino acids 82 to 749, and preferably a sequence or sequences which comprises the catalytic active centre, of type IV cPLA₂ protein from human monocyte (U937) cells. In a further alternative embodiment, the term "a protein immunologically homologous to type IV cPLA₂" means a protein that binds specifically to an antibody or antibodies raised against an epitope or epitopes from the peptide sequence of amino acids 241 to 260 of type IV cPLA₂ protein from human monocyte (U937) cells, or a synthetic peptide matching the sequence of amino acids from the peptide sequence of amino acids 241 to 260 of type IV cPLA₂ protein from human monocyte (U937) cells.

According to a third aspect of the present invention, there is provided a method of diagnosis of a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cPLA₂ protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells. The method may further comprise the step of determining the level of type IV cPLA₂ protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells and, optimally, comparing this level with a control level.

As used herein, the term "highly unsaturated fatty acids" includes all fatty acids released by action of the type IV cPLA₂ enzyme. In an embodiment of the invention the term "highly unsaturated fatty acids" includes fatty acids having 3 or more carbon-carbon double bonds. In particular, the term includes the essential fatty acids, particularly the fatty acids of the group comprising dihomo-gammalinolenic acid (DGLA; 8,11,14-eicosatrienoic acid), arachidonic acid (AA; 5,8,11,14-eicosatetraenoic acid), adrenic acid (7,10,13,16-docosatetraenoic acid), 4,7,10,13,16-docosapentaenoic acid, stearidonic acid (SA; 6,9,12,15-octadecatetraenoic acid), 8,11,14,17-eicosatetraenoic acid, eicosapentaenoic acid (EPA; 5,8,11,14,17-eicosapentaenoic acid), docosapentaenoic acid (DPA; 7,10,13,16,19-

docosapentaenoic acid) and docosahexaenoic acid (DHA; 4,7,10,13,16,19-docosahexaenoic acid).

According to a fourth aspect of the invention, there is provided a method of monitoring the effectiveness of medication administered to a patient suffering from a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cPLA₂ protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells. The method may, for example, comprise the steps of administering to a patient a compound to be tested, determining the level of type IV cPLA₂ protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells and, optimally, comparing this level with a control level or with a level or levels determined at an earlier stage of the medication regime or before the medication regime commenced.

According to a fifth aspect of the invention, there is provided a method of drug development for a disease in which dysfunction of the cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cPLA₂ protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells. The method may, for example, be used in the screening of compounds for use in the treatment of a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, the method comprising the steps of administering to a patient or test animal a compound to be tested, determining the level of type IV cPLA₂ protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells and, optimally, comparing the level with a control level.

25

The invention is particularly concerned with diseases in which dysfunction of cell signalling systems involving arachidonic acid, dihomogammalinolenic acid, eicosapentaenoic acid, docosapentaenoic acid and/or docosahexaenoic acid is implicated. More particularly, the invention is concerned with diseases in which dysfunction of cell signalling systems involving arachidonic acid is implicated.

30

The disease conditions in which the identification of type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂ in or on red cells may be useful include:

- 1) schizophrenia, in which increased cPLA₂ expression and activity is a proposed mechanism in disease development;
- 2) bipolar or manic depressive illness, in which cPLA₂ abnormality may be present;
- 3) cachexia, in which tumour necrosis factor promotes cPLA₂ activity;
- 4) brain injury, including stroke and mechanical injury, in which cPLA₂ may be released from damaged membranes or as part of the process of apoptosis;
- 5) dyslexia, in which abnormal cPLA₂ activity may be present; and
- 6) any other disease or disease process in which type IV cPLA₂ activity or concentration is increased or decreased from normal levels, particularly a disease or disease process in which type IV cPLA₂ activity or concentration is increased.

The assays and methods of the invention may comprise the steps of collecting a sample of blood from a subject, and detecting the proteins *ex vivo*. Preferably, the assays and methods further comprise one or more of the steps of separating the red cells from the other blood components, disrupting the red cells by a method such as sonication, nitrogen cavitation, freezing or lysis, and detecting the proteins either directly or following a protein separation technique. Another application for the assays and methods of the invention include their employment on whole blood, with or without the requirement of prior separation of the red cells, and such applications would include, for example, a near-patient testing diagnostic strip, cartridge, or device.

In a preferred embodiment, the assays and methods of the invention comprise the detection in or on red blood cells of one or more proteins from one or more of three particular groups of proteins. The proteins are grouped by apparent molecular weight as measured using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) with western blot and can be designated as follows:

30

Group A, comprising one or more proteins of apparent molecular weight in the range of 80 to 110 kDa, particularly in the range of 90 to 105 kDa;

Group B, comprising more or more proteins of apparent molecular weight in the range of 70 to 80 kDa;

Group C, comprising one or more proteins of apparent molecular weight in the range of 50 to 60 kDa.

5

It is considered that the proteins in a given group may be structurally related, small variations in apparent molecular weight between the proteins in a given group possibly being due to the extent of phosphorylation. However, it is not intended that the scope of the invention be limited by this theory. Variations in apparent molecular weight among
10 proteins of a given group may simply be due to variations in the length of the amino acid sequence of the protein or protein fragment.

These proteins react immunologically with antibodies to cPLA₂. The proteins can be identified by an antibody or antibodies which react with an epitope or epitopes present in a
15 region of the type IV cPLA₂ protein which does not share sequence homology with other proteins, for example a region other than the calcium-binding portion of the protein. The proteins can also be identified by using a first antibody (a "capture antibody") which reacts with an epitope or epitopes present in a sequence having homology with other proteins, for example, the calcium binding portion of the type IV cPLA₂ protein, and a second antibody
20 (a "detection antibody") which reacts with an epitope or epitopes in a region of the protein which does not have homology with other proteins in order to provide the necessary specificity. Protein detection and identification is discussed in more detail below.

It is considered that the proteins or protein fragments isolated from in or on red
25 blood cells may be the same as the type IV cPLA₂ protein, or fragments thereof, found in human monocyte (U937) cells. Thus, it is considered that the proteins having apparent molecular weights in the range of 80 to 110 kDa (particularly 90 to 105 kDa), in the range 70 to 80 kDa and in the range 50 to 60 kDa may be either intact type IV cPLA₂ or major components of type IV cPLA₂. However, it is not intended that the scope of the invention
30 be limited by this theory.

According to a further aspect of the invention there is provided a protein obtainable by isolation from red blood cells, said protein being immunologically homologous to type

IV cPLA₂. Said protein may exist in the body in the form of a protein having a molecular weight in the range 80 to 110 kDa (and particularly in the range of 90 to 105 kDa) or in the form of a protein having a molecular weight in the range 70 to 80 kDa or in the form of a protein having a molecular weight in the range 50 to 60 kDa.

5

Protein Separation

The type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂ proteins are typically separated from the other proteins of red blood cells by SDS PAGE but a variety of other protein separation techniques may be used, including native
10 polyacrylamide gel electrophoresis and various column separation techniques such as fast protein liquid chromatography and variants of sepharose or other commercially available columns. Two dimensional electrophoretic techniques may also be used. As noted above, prior protein separation is not always necessary and the type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂ may be detected in red cells by
15 immunological means without the necessity of prior protein separation.

Protein Detection

The detection of type IV cPLA₂ proteins and/or proteins immunologically homologous to type IV cPLA₂ can be achieved by a wide range of protein detection
20 procedures including:

- 1) enzyme linked immunoassay, radioimmunoassay, luminescence immunoassay, fluorescence immunoassay or any other variant of competitive or tagged antibody immunoassay, including biosensor technology (evanescent wave optical biosensor);
- 2) immunofluorescence or other immunoassay on red blood cells in smears, droplets,
25 films, fixed histological sections or tissue samples;
- 3) *in vitro* tests in which the protein is recognised by a specific polyclonal or monoclonal antibody and the specific antibody is itself recognised in a Coombs-type test; and
- 4) enzymic substrate assay of type IV cPLA₂ proteins utilising natural or artificial
30 phospholipid substrates together with specific inhibitors of the other phospholipase enzymes.

In one embodiment of the invention, protein detection is achieved using diagnostic strips, cartridges or devices suitable for near-patient testing which detect the proteins using any of the above techniques or any other technique known in the art.

5 In a preferred embodiment, the proteins are detected using either a polyclonal or a monoclonal antibody or a combination thereof. Table 1 provides examples of antibodies suitable for use in the assays of the present invention for the detection of type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂.

10 Suitable antibodies or combinations of antibodies for use in the present invention can also include one or more of, for example, a polyclonal antibody raised against an epitope of the peptide chain comprising amino acids 730 to 749 of type IV cPLA₂ from U937 cells, or an extended or different amino acid sequence from the C-terminal end of the molecule; an antibody or antibodies raised against a mid-molecule peptide sequence or
15 sequences which comprise the catalytic active site of type IV cPLA₂ from U937 cells; an antibody or antibodies raised against an epitope from the N-terminal part of the sequence (amino acids 1 to 216); and an antibody or antibodies raised against another epitope or epitopes from the amino acid sequence of type IV cPLA₂ protein from U937 cells between amino acids 82 and 749.

20

Table 1

ANTIGEN	TYPE	PRODUCTION METHOD	SOURCE	DETECTS cPLA ₂ - LIKE PROTEINS IN RED CELLS
Human type IV cPLA ₂ synthetic peptide from mid molecule	Polyclonal IgG	Raised in Rabbits	Cayman Chemical	Yes
Human type IV cPLA ₂ synthetic peptide of a 24 amino acid sequence from the C-terminal domain	Polyclonal IgG	Raised in Sheep	The Binding Site	Yes
Human cPLA ₂ synthetic peptide to amino terminal (amino acids 1-216)	Monoclonal IgG	Mouse	Chemicon International Inc.	Yes
Human type IV cPLA ₂ synthetic peptide mid molecule sequence (amino acids 241 to 260) ^a	Polyclonal IgG	Raised in Sheep	In-house production	Yes

- 5 a: This antibody is prepared using as antigen a synthetic peptide comprising amino acids 241 to 260 of type IV cPLA₂ (as found in human monocytes, U937 cells), coupled to ovalbumin. The antigen is injected into sheep with Freund's adjuvant combining the intra-muscular and subcutaneous routes in standard approved protocol. The resulting antiserum was purified initially using Protein A and further purified using an affinity matrix carrying the peptide 241 to 260 not coupled to ovalbumin, to provide an affinity purified IgG antibody.

10 The recognition of type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂ in an accessible component of blood opens the way to their use as follows:

- a) Diagnostic use by direct immunoassay of their level.
- b) Use in a diagnostic sense indirectly as part of a Coombs-type test.
- 15 c) Recognition by immunofluorescence on or in red blood cells on slide or smear or tissue preparation.

- d) Use in an immune precipitation or other reaction to recognise type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂ in whole blood samples in near-patient testing.
- e) Use in monitoring of treatments which are directed to suppress PLA₂ activity or concentration.
- f) Use in the research for agents which suppress PLA₂ activity or concentration for drug discovery.

The invention will now be described in detail with reference to the following examples. It will be appreciated that the invention is described by way of example and modification of detail may be made without departing from the scope of the invention.

EXAMPLES

I. Collection of Samples

The collection of samples for protein separation and detection were performed as follows:

- 1) Samples of venous blood (4 to 6 ml) were collected by venepuncture using EDTA at standard concentration for anticoagulation (Vacutainer ® or Starstedt Monovette ®). Other appropriate anticoagulants known to persons skilled in the art may also be used.
- 2) Within 3 minutes of the sample being withdrawn, protease inhibitors were added. To the 4 or 6 ml volume of blood were added 0.5 ml of a protease inhibitor cocktail, freshly prepared, as follows:
To 3 mls of Aprotinin (Trasylol ®) concentration 10,000 Kallikrein inactivator units per ml was added 2 mg phenylmethanesulphonyl fluoride (PMSF) and 0.5 mg leupeptin. Other appropriate inhibitor preparations known to persons skilled in the art may also be used.

3) The whole blood sample was then centrifuged, at 3000 rpm (1,000 g), for 10 minutes. Plasma was removed and the layer of white cells and platelets (the buffy coat) removed by plastic pipette, to leave the red cells in the tube.

5 4) A volume of ice cold phosphate buffered saline PBS pH 7.4 or other appropriate buffer, equal in volume to the red cells was added and red cells and buffer were mixed by inversion.

10 5) The cells in buffer were then centrifuged, at 1,000 g, repeating steps 3 and 4 three times, providing washed red cells.

15 6) The washed red cells were frozen in 0.5 ml aliquots were suspended in 0.5 ml of buffer, prepared as follows: 0.37 g KCl, 0.74 g disodium EDTA, 3.0 g Tris, 9 g NaCl in 1 litre of water, adjusted to pH 7.4 with HCl. (Kramer *et al. J. Biol. Chem.* 266, 5268-5272). The washed red cells may alternatively be frozen directly as packed cells.

20 In a simplified procedure, blood is collected into an EDTA vacutainer, centrifuged at 3000 rpm (1000g) for 10 minutes, the plasma and the buffy coat removed by aspiration and the packed red cells stored frozen.

25 7) These samples were stored frozen at -80°C or used directly after brief freezing to provide lysis for SDS polyacrylamide gel electrophoresis or for immunoassay in a calibrated assay. Where packed cells are stored frozen prior to use they are thawed into the buffer described in step (6) above.

30 Where the simplified procedure is employed, protease inhibitor is included in the buffer added to the red cells for the thawing process in the form of one tablet of COMPLETE™ protease inhibitor (Boehringer Mannheim) per 200 ml of buffer.

II. Protein Separation and Detection using SDS PAGE

Protein separation and detection was achieved using SDS PAGE as described below.

In SDS PAGE, the sample was treated with a volume of sample buffer, comprising Tris buffer pH 6.8 containing 6% SDS, 0.5% dithiothreitol and 20 ml glycerol per 100 ml. (Alternative buffers known to persons skilled in the art may be used). Lysate was added to
5 give a 4-fold or greater dilution of the lysate in sample buffer. The sample was transferred to the standard SDS 7.5% polyacrylamide gel for electrophoresis. After electrophoresis the proteins were transferred from the gel to a membrane by electroblotting.

The test membrane was reacted with polyclonal antibody to mid-molecule type IV
10 cPLA₂ raised in rabbit and then anti rabbit IgG antibody raised in swine which has been coupled to horse raddish peroxidase to demonstrate the presence of the cPLA₂ antigen. The blank membrane was reacted with anti rabbit IgG antibody raised in swine which has been coupled to horse raddish peroxidase. Any bands observed on the blank membrane are due to the presence of antigens other than the cPLA₂ antigen.

15 Figure 1a and 1b show two western blot analyses (figure 1a is the test membrane; figure 1b is the blank membrane) on the following samples:

Lane 1: Molecular weight markers
20 Lane 2: Cell cytosol from insect cells infected with Baculovirus expressing type IV cPLA₂.
Lanes 3-12: Patient samples. The samples were taken from schizophrenic patients on clozapine (lanes 4, 7, 9 and 10), schizophrenic patients on neuroleptic drugs (lanes 8 and 12) and from control patients (lanes 3, 5, 6 and 11).

25 The patient samples on the test membrane show three band types grouped by molecular weight as described above:

30 **Group A:** one band is observed above the 97 kDa molecular weight marker, having a molecular weight of about 100 to 105 kDa, and one band is observed below the 97 kDa molecular weight marker, having a molecular weight of about 90 to 95 kDa;

Group B: a single band is observed with molecular weight around 70 kDa;

Group C: three bands are observed with molecular weights around 60 kDa. Two of the bands in this molecular weight group are believed to be type IV cPLA₂ proteins. The most distinct of these also appears on the blank membrane, has a less specific immunological response and may not be a type IV cPLA₂ protein.

In summary, the red cell lysates contained five proteins, two in the range of about 90 to about 105 kDa, one in the range of about 70 to about 80 kDa, and two in the range of about 50 to about 60 kDa, which reacted specifically in SDS PAGE western blot analysis with polyclonal antibody prepared against mid-molecule sequences of type IV cPLA₂.

As noted above the bands grouped in Groups A, B and C may represent, respectively, the intact type IV cPLA₂ molecule in differing stages of phosphorylation and two groups of peptide sequences of type IV cPLA₂ proteins which have lost amino acids by protein degradation. However, as stated above, it is not intended that the scope of the invention be limited by this theory. The bands grouped in Groups A, B and C could also represent intact type IV cPLA₂ and fragments of type IV cPLA₂ differing in the length of amino acid sequence.

III. Protein Detection using Enzyme Linked Immunoassay (ELISA)

Immunoassay, specifically enzyme linked immunoassay (ELISA), was also used to detect red cell type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂. This method uses a luminescence end point for protein detection.

Samples are collected and prepared as hereinbefore described. Samples of red cells for analysis were stored at -80°C.

The following reagents are required for ELISA:

- 1) Coating buffer, pH 9.6
1.59 g sodium carbonate, 2.93 g sodium bicarbonate in 1 litre deionised water;
- 2) Wash buffer, pH 7.4
6.07 g Tris, 0.2 g potassium chloride, 29.2 g sodium chloride in 800 ml deionised water adjusted to pH 7.4 with hydrochloric acid and made up to 1 litre;

- 3) Buffer for standard/sample diluent, pH 7.4
0.37 g potassium chloride, 0.74 g disodium ethylenediaminetetra-acetate, 3g Tris,
8.58 g sodium chloride in 800 mls deionised water adjusted to pH 7.4 and made up to
1 litre;
- 5 4) Standard/sample diluent
200 ml of buffer (3) to which is added 0.2 g human albumin and 1 tablet of
Complete[®] protease inhibitors (Boehringer Mannheim);
- 5) Citrate solution, pH 7.4
2.94 sodium citrate dissolved in 800 ml deionised water adjusted to pH7.4 with
10 hydrochloric acid and made up to 1 litre;
- 6) Antibody conjugate reagent
5 mls reagent (2), 6 mls Roti-Block [®] (Rotech Scientific, Milton Keynes, UK), 0.2
ml reagent (5), 0.012 g human serum albumin and 1 ml of the in-house anti-cPLA₂
IgG (as described herein) - alkaline phosphatase conjugate;
- 15 7) Luminescence reagent containing Lumi-Phos [®] 530 (buffered solution containing
dioxetane Lumigen [®] PPD, fluorescer and surfactant) (obtained from Beckman
Coulter, UK)

The assay is performed using 96 well microtitre plates according to the following
20 procedure:

- 1) The capture antibody (obtained from The Binding Site, Birmingham, UK) was diluted
1:10 with saline and stored in 500 µl aliquots at -20°C. One aliquot of this antibody is
added to 11.5 ml coating buffer, mixed and 100 µl of diluted capture antibody is
25 pipetted into each well of a white microtitre plate to coat the wells of the plate with
capture antibody. The plate is sealed and stored at 4°C overnight. Prior to use, the
plate is then washed four times with wash buffer pH 7.4 (reagent (2) as hereinbefore
described).
- 2) The plate is blocked by pipetting into each well 300 µl of Roti-Block[®] diluted 1:2
with reagent (2). Blocking takes 90 minutes at 25°C. Blocking reagent is removed
30 by washing four times with reagent (2).
- 3) Duplicate aliquots (100 µl) of sample or standard are then pipetted into each
microtitre plate well and the plate incubated for 90 minutes at 25°C. The incubation
is stopped by washing the plate four times with reagent (2).

4) The second antibody (the conjugated antibody, reagent (6)) is then added. Antibody is conjugated to alkaline phosphatase by standard techniques (Duncan *et al.*, *Analytical Biochemistry* 132, 68-73). 100 µl of the antibody conjugate, reagent (6), is added to each well and the plate incubated for 90 minutes at 25°C.

5) At the end of this incubation, the plate is washed 8 times with reagent (2).

6) Luminescence is developed in the wells of the plate by adding 100 µl luminescence reagent (7) to each well and incubating for 20 minutes with shaking in a luminometer (Luminoscan Labsystems, Helsinki).

7) Luminescence in relative light units for a given sample is measured and compared with that of standard type IV cPLA₂ preparations. The use of standard type IV cPLA₂ preparations can be used to derive a calibration curve for an assay for cPLA₂. Figure 2 shows a calibration curve derived from 10 separate assays with the standard error of the mean marked.

8) Sample preparation

Prior to analysis, the frozen red blood cells were thawed, centrifuged at 10,000 g for 5 minutes and diluted 1:40 with sample diluent (reagent (4)).

9) Standard preparation

A U937 cell cytosol was utilised as a standard. This was prepared from U937 human monocyte culture (Clark *et al.*, *Proc. Nat. Acad. Sci. USA*, 87, 7708-7712). Cells were harvested from culture, resuspended in standard/sample diluent, omitting the albumin content and with the addition of 11.6 g/100 ml sucrose. The cells were disrupted by nitrogen cavitation in a Parr bomb and the resulting preparation centrifuged at 150,000 g for 1 hour at 4°C. The supernatant, a U937 cell cytosol, was aliquoted and stored at -80°C for standardisation. Western blot analysis of dilutions of this material allowed allocation of a value for type IV cPLA₂ content from the point at which type IV cPLA₂ was just detected by Western blot. The standard is stable at -80°C. All assays included internal quality control samples of an aliquoted red cell haemolysate.

10) Units for the estimation of type IV cPLA₂ in red cells haemolysates are µg cPLA₂ per g haemoglobin.

Haemoglobin amounts were estimated by diluting the sample to 0.04% ammonia and reading the optical density at 540 nm, standardised against haemoglobin of known concentration.

Within-batch percentage coefficient of variation (CV%), which is a measurement of relative variation, i.e. the standard deviation expressed as a percentage of the arithmetic mean, typically measured 8.6 % and between-batch CV% typically measured 10.8%. These were measured at 9.0 ng cPLA₂ per g of haemoglobin (ng/gHb) and 9.7 ng/gHb respectively.

IV. Measurement of Type IV cPLA₂ Levels in Red Blood Cells in Various Patient Groups

As an illustration of the clinical application of the measurement in red cells of type IV cPLA₂ protein or protein immunologically homologous to type IV cPLA₂, various blood samples were collected from groups of patients each with a defined psychiatric illness and from a control group. The samples from each patient group in this study were analysed using the ELISA method hereinbefore described. The patients within each group met stated criteria for their clinical diagnosis, as detailed below. Samples were collected using steps 1 to 7 hereinbefore described. Specimens were also collected and prepared omitting washing steps 4 to 5. This alternative shortened cell preparation method, employing only steps 1 to 3 and 6 to 7 was examined for its influence on the assayed levels of cPLA₂. Comparisons were made of samples given the full wash procedure and samples using the shortened procedure. No significant difference was found either within groups or combining the results in all groups when the two red cell preparation procedures were compared. The patients groups were as follows:

Group 1: Schizophrenia

49 Patients who met the DSM IV criteria for the diagnosis of schizophrenia (Diagnostic and Statistical Manual of Mental Disorders 4th Edition, American Psychiatric Association 1994);

36 Males and 13 females, age range 17 to 66 with mean age 37.3 +/- 11.9 years.

Group 2: Dyslexia

27 Volunteers with recognised criteria for identification of Dyslexia, i.e. a difference of 15 points or more between Wechsler Adult Intelligence Scale Revised (WAIS-R) pro-rated equivalent IQ (© The Psychological Corporation Limited 1986) and Wide Range Achievement Test score (WRAT) (Wilkinson © Wide Range Inc, 1993) or reaching a

Bangor Dyslexia Test score (T.R. Miles in Dyslexia, The Pattern of Difficulties. Grenada, 1983) equal to or greater than 7;

17 Males and 10 females of age range 16 to 67 with mean age 35.4 +/- 13.2 years.

Group 3: Controls

5 51 volunteers comprised the control group;

25 Males and 26 females, age range 16 to 57 with mean age 35.4 +/- 12.4 years.

The results of the study are displayed in Figures 3A, 3B and 3C which show the frequency histogram of red cell type IV cPLA₂ or proteins or proteins immunologically homologous to type IV cPLA₂ in µg cPLA₂ per g haemoglobin (Hb) as estimated by the ELISA method hereinbefore described. Figures 3A, 3B and 3C illustrate, respectively, the control group, the schizophrenic group and the dyslexic group.

The distribution of the results of the assays for red cell type IV cPLA₂ or proteins or proteins immunologically homologous to type IV cPLA₂ measured as µg per g haemoglobin (Hb) was positively skewed (Fig 3) and non-parametric tests were applied in analysis. Mann Whitney U test of the schizophrenia patient group and controls reveal a highly significant elevation of red cell cPLA₂ in the schizophrenia group compared with the control group ($P < 0.0001$). There was a lesser elevation of red cell cPLA₂ in the dyslexic subjects compared with controls ($P < 0.001$). Determination of a reference range encompassing 95% of the control group for red cell cPLA₂ permitted determination of an upper cut off point for the reference range for red cell cPLA₂ of 2.8 µg per g Hb. This is not an absolute value but is derived from the standardisation procedure used for these studies, as hereinbefore described.

25

Confirmation of the ELISA analysis of the type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂ in the red cell haemolysates may be obtained by using SDS PAGE and western blot analysis using the techniques previously described. Samples from a patient in the control group and from a patient in the schizophrenic patient group (group I) were subjected to further analysis using SDS PAGE and western blot. The group I sample was taken from a patient that had been shown by ELISA to have high levels of type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂ in the red cell haemolysates.

30

Figure 4 illustrates the type IV cPLA₂ proteins or proteins immunologically homologous to type IV cPLA₂ in the red cell haemolysates, and the proteins observed in a red cell haemolysate from a control patient, as observed by SDS PAGE/western blot.

- 5 Protein of the molecular weight of cPLA₂ protein from human monocyte U937 cells is observed in the haemolysate from the schizophrenic patient; there was no protein detected which had this molecular weight in the haemolysate from the control subject. The various samples in the western blot analysis shown in Figure 4 are as follows:

- 10 Lane1: Molecular weight markers
Lane 2: Cytosol from insect cells infected with baculovirus expressing type IV cPLA₂
Lane 3: Cytosol from human monocyte U937 cells containing a cPLA₂ protein
Lane 4: Red cell haemolysate from a control subject
Lane 5: Red cell haemolysate from a schizophrenia subject

< the purpose of >
 << wherein said assay is >>

CLAIMS

Use of red blood cells in an

1. ~~An assay for detecting type IV cytosolic phospholipase A₂ (cPLA₂) or a protein immunologically homologous to type IV cPLA₂, the assay comprising use of red blood cells~~
2. ~~An assay~~ according to claim 1 ^{Use} << >> for use in the diagnosis of a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated.
3. ~~An assay~~ according to claim 1 ^{Use} << >> for use in monitoring the effectiveness of medication administered to a patient suffering from a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated
4. ~~An assay~~ according to claim 1 ^{Use} << >> for use in drug development for a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated
5. A method of diagnosis of a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cytosolic phospholipase A₂ (cPLA₂) protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells.
6. A method of monitoring the effectiveness of medication administered to a patient suffering from a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cytosolic phospholipase A₂ (cPLA₂) protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells.
7. A method of drug development for a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cytosolic phospholipase A₂ (cPLA₂) protein or a protein immunologically homologous to type IV cPLA₂ in or on red blood cells.

Use

8. ~~An assay~~ or method according to any one of claims 1 to 7 wherein the red blood cells are isolated from the human body.

Use

- 5 9. ~~An assay~~ or method according to any one of claims 1 to 7 wherein said assay or method comprises use of a whole blood sample without prior isolation of said red blood cells.

Use

- 10 10. ~~An assay~~ or method according to any one of claims 2 to 9 wherein said disease is a disease or disease process in which type IV cPLA₂ activity or concentration is altered from normal levels.

Use

- 15 11. ~~An assay~~ or method according to anyone of claims 2 to 9 wherein said disease is a disease or disease process in which type IV cPLA₂ activity or concentration is increased.

Use

- 20 12. ~~An assay~~ or method according to any one of claims 2 to 11 wherein the disease is schizophrenia, dyslexia, bipolar or manic depressive illness, cachexia or brain injury.

Use

13. ~~An assay~~ or method according to claim 12 wherein the brain injury is stroke or mechanical brain injury.

Use

- 25 14. ~~An assay~~ or method according to any one of claims 1 to 13 wherein the type IV cPLA₂ protein or the protein immunologically homologous to type IV cPLA₂ has a molecular weight in the range 80 to 110 kDa or in the range 70 to 80 kDa or in the range 50 to 60 kDa.

Use

- 30 15. ~~An assay~~ or method according to any one of claims 1 to 13 wherein the type IV cPLA₂ protein or the protein immunologically homologous to type IV cPLA₂ has a molecular weight in the range 90 to 105 kDa or in the range 70 to 80 kDa or in the range 50 to 60 kDa.

<Wherein said assay or method
comprises>

22

Use

16. ~~An assay~~ or method according to any preceding claim ^{<>} ~~comprising~~ the steps of collecting a sample of blood from a subject and detecting the proteins *ex vivo*.

Use

17. ~~An assay~~ or method according to claim 16 ^{<>} ~~further comprising~~ one or more of the steps of separating the red cells from the other blood components, disrupting the red cells, detecting the proteins either directly or following a protein separation technique.

Use

18. ~~An assay~~ or method according to claim 17 wherein the red cells are disrupted by sonication, freezing, nitrogen cavitation or lysis.

Use

19. ~~An assay~~ or method according to any preceding claim wherein said proteins are detected by immunoassay.

Use

20. ~~An assay~~ or method according to any preceding claim wherein said proteins are detected using an antibody or antibodies that recognise an epitope or epitopes from amino acids 82 to 749 of type IV cPLA₂ protein from human monocyte (U937) cells.

Use

21. ~~An assay~~ or method according to any preceding claim wherein said proteins are detected using an antibody or antibodies raised against an epitope or epitopes from amino acids 82 to 749 of type IV cPLA₂ protein from human monocyte (U937) cells) or raised against an epitope or epitopes of a synthetic peptide matching amino acids 82 to 749 of type IV cPLA₂ protein from human monocyte (U937) cells.

Use

22. ~~An assay~~ or method according to claim 20 or 21 wherein said epitope or epitopes are from a peptide sequence or sequences which comprise the catalytic centre of type IV cPLA₂ protein from human monocyte (U937) cells.

Use

23. ~~An assay~~ or method according to claim 20 or 21 wherein said epitope or epitopes are from the peptide sequence of amino acids 241 to 260 of type IV cPLA₂ protein from human monocyte (U937) cells.

ART 34 NOT

Use

24. ~~An assay~~ or method according to claim 19 wherein said proteins are detected using an antibody or antibodies raised against an epitope or epitopes from amino acids 1 to 216 of type IV cPLA₂ protein from human monocyte (U937) cells.

Use

- 5 25. ~~An assay~~ or method according to claims 20, 21, 22, 23 or 24 wherein two or more of the antibodies are used in combination or in sequence to detect the said proteins with the required specificity.

Use

- 10 26. ~~An assay~~ or method according to any of claims 1 to 18 for detecting type IV cPLA₂ wherein said proteins are detected by substrate assay.

other than type IV cPLA₂

- 15 27. A protein ^{other than type IV cPLA₂} obtainable by isolation from red blood cells, said protein being immunologically homologous to type IV cPLA₂ and having a molecular weight in the range 80 to 110 kDa or a molecular weight in the range 70 to 80 kDa or a molecular weight in the range 50 to 60 kDa.

- 20 28. A protein according to claim 27, said protein being immunologically homologous to type IV cPLA₂ and having a molecular weight in the range 90 to 105 kDa or a molecular weight in the range 70 to 80 kDa or a molecular weight in the range 50 to 60 kDa.

- 25 29. A diagnostic kit comprising means for disrupting red blood cells and further comprising an antibody or antibodies to a protein obtainable by isolation from red blood cells, said protein being type IV cPLA₂ protein or a protein immunologically homologous to type IV cPLA₂.

- 30 30. A diagnostic kit according to claim ²⁹~~28~~ wherein said antibody or antibodies is/are raised against an epitope or epitopes from amino acids 82 to 749 of type IV cPLA₂ protein from human monocyte (U937) cells.

31. A diagnostic kit according to claim ²⁹~~28~~ wherein said antibody or antibodies is/are raised against an epitope or epitopes from a peptide sequence or sequences which

1/4

FIG. 1a




FIG. 1b





FIG. 2



3/4

FIG. 3A




FIG. 3B




FIG. 3C





FIG. 4



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

DIAGNOSTIC TEST

the Specification of which

☒ is attached hereto

☒ was filed on 8 March 2000

as International Application No. PCT/GB00/00845

I hereby state that I have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

<u>APPLICATION NUMBER</u>	<u>PRIOR FOREIGN FILED APPLICATION(S) COUNTRY</u>	<u>(MONTH/DAY/YYYY)</u>	<u>PRIORITY CLAIMED</u>
9905417.3	Great Britain	March 9, 1999	YES
9919952.3	Great Britain	August 23, 1999	YES

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER(S)

FILING DATE (MM/DD/YYYY)



I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent <u>Application No.</u>	PCT Parent <u>Number</u>	Parent Filing <u>(MM/DD/YYYY)</u>	Parent Patent <u>Number (if applicable)</u>
---------------------------------------	-----------------------------	--------------------------------------	--

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from **CARMAELS & RANSFORD** as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

I hereby appoint as my attorneys or agents the registered persons identified under

Customer No. 23565

for the law firm of Klauber & Jackson, said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to **Customer No. 23565**.

DAVID A. JACKSON, ESQ.
KLAUBER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-CE
FULL NAME OF FIRST OR SOLE INVENTOR: Alastair Campbell Agnew GLEN

COUNTRY OF CITIZENSHIP: Great Britain

FULL RESIDENCE ADDRESS: 276 A Nithsdale Road
Glasgow G41 5LP
United Kingdom GBN

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR Alastair Agnew

DATE 12th July 2001

2-CC
FULL NAME OF SECOND JOINT INVENTOR: Donald John MCDONALD

COUNTRY OF CITIZENSHIP: Great Britain

FULL RESIDENCE ADDRESS: 186 Cumbernauld Road
Glasgow G73 6HA
United Kingdom GBN

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR DJ McDonald

DATE 12th July 2001